Teva, Merck agree to 2017 date for Vytorin copies

Teva Pharmaceutical Industries has agreed that it won't sell generic versions of Merck's ($MRK) cholesterol drugs Vytorin and Zetia until 2017, settling patent disputes between the two companies. Merck still faces a patent fight with Mylan over Zetia and Vytorin, however. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.